Abstract
Background: Valosin-containing protein (VCP, also known as p97) exhibits antiapoptotic function and metastasis by activation of nuclear factor kappa-B signaling pathway. Our previous study showed that VCP expression level correlated with prognosis of hepatocellular and gastric carcinoma. In the present study, association of VCP expression with lymph node metastasis and prognosis of pancreatic ductal adenocarcinoma (PDAC) was examined.
Methods: VCP expression in 83 patients (46 males and 37 females) of ages ranging from 43 to 80 (median, 66) years who had undergone curative surgery for primary PDAC was analyzed by immunohistochemistry, in which staining intensity in tumor cells was categorized as weaker or equal to (low expression) or stronger (high expression) than that in noncancerous ductal tissue.
Results: Thirty-two tumors (38.6%) and 51 tumors (61.4%) were classified as low-VCP-expressing and high-VCP-expressing tumors, respectively. VCP expression correlated significantly with lymph node metastasis (P < .01) but not with various clinicopathologic factors, including age, gender, and histologic differentiation. Multivariate analysis revealed VCP expression as an independent prognosticator for both disease-free and overall survival, along with histologic differentiation, T stage of pathologic tumor-node-metastasis (pTNM) classification, and lymph node metastasis. Furthermore, VCP expression was a prognosticator for disease-free and overall survival in each relatively early stage (I or II) and advanced stage (III) group of pTNM classification.
Conclusions: Our results indicate the potential usefulness of VCP expression as a marker of metastasis and overall prognosis of PDAC.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Niederhuber JE, Brennan MF, Menck HR. The National Cancer Data Base report on pancreatic cancer. Cancer 1995;76:1671–1677.
Gudjonsson B. Cancer of the pancreas: 50 years of surgery. Cancer 1987;60:2284–2303.
Rosenberg L. Pancreatic cancer: a review of emerging therapies. Drugs 2000;59:1071–1089.
Lorenz M, Heinrich S, Staib-Sebler E, et al. Regional chemotherapy in the treatment of advanced pancreatic cancer: is it relevant?. Eur J Cancer 2000;36:957–965.
Brennan MF, Kinsella TJ, Casper ES Cancer of the pancreas. In: de Vita VT, Helmann S, Rosenberg SA. Cancer: Principles and Practice of Oncology. Philadelphia: JB Lippincott, 1993:849–82.
Warshaw AL, Fernandez-del Castillo C. Pancreatic carcinoma. N Engl J Med 1992;326:455–465.
Fidler IJ, Kripke ML. Metastasis results from preexisting variant cells within a malignant tumor. Science 1977;197:893–895.
Fidler IJ. The evolution of biological heterogeneity in metastatic neoplasms. In: Nicolson GL, Milas L. Cancer Invasion and Metastasis: Biologic and Therapeutic Aspects. New York: Raven Press, 1984:5–30.
Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988;53:549–554.
Scarpa A, Capelli P, Mukai K, et al. Pancreatic adenocarcinomas frequently show p53 gene mutations. Am J Pathol 1993;142:1534–1543.
Barton CM, Hall PA, Hughes CM, Gullick WJ, Lemoine NR. Transforming growth factor alpha and epidermal growth factor in human pancreatic cancer. J Pathol 1991;163:111–116.
Asai T, Tomita Y, Nakatsuka S, et al. VCP (P97) regulates NFkappaB signaling pathway, which is important for metastasis of osteosarcoma cell line. Jpn J Cancer Res 2002;93:296–304.
Dai RM, Chen E, Longo DL, Gorbea CM, Li CC. Involvement of valosin-containing protein, an ATPase Co-purified with IkappaBalpha and 26 S proteasome, in ubiquitin-proteasome-mediated degradation of IkappaBalpha. J Biol Chem 1998;273:3562–3573.
Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ. The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 1999;5:119–127.
Yamamoto S, Tomita Y, Nakamori S, et al. Elevated expression of Valosin-containing protein (P97) in hepatocellular carcinoma is correlated with increased incidence of tumor recurrence. J Clin Oncol 2003;21:447–452.
Sobin LH, Wittekind CH. TNM classification of malignant tumours, 6th ed. New York: John Wiley & Sons, 2002:93–6.
Muller JM, Meyer HH, Ruhrberg C, Stamp GW, Warren G, Shima DT. The mouse p97 (CDC48) gene: genomic structure, definition of transcriptional regulatory sequences, gene expression, and characterization of a pseudogene. J Biol Chem 1999;274:10154–10162.
Kaplan EL, Meier P. Non-parametric estimation for incomplete observations. J Am Stat Assoc 1958;53:457–481.
Cox DR. Regression models and life tables. J R Stat Soc 1972;34:187–220.
Cameron JL, Crist DW, Sitzmann JV, et al. Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer. Am J Surg 1991;161:120–124.
Vuylsteke RJ, van Leeuwen PA, Meijer S, et al. Sampling tumor-draining lymph nodes for phenotypic and functional analysis of dendritic cells and T cells. Am J Pathol 2002;161:19–26.
Jacobs AD. Gemcitabine-based therapy in pancreas cancer: gemcitabine-docetaxel and other novel combinations. Cancer 2002;923–7.
Kachnic LA, Shaw JE, Manning MA, Lauve AD, Neifeld JP. Gemcitabine following radiotherapy with concurrent 5-fluorouracil for nonmetastatic adenocarcinoma of the pancreas. Int J Cancer 2001;96:132–139.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yamamoto, S., Tomita, Y., Hoshida, Y. et al. Increased Expression of Valosin-Containing Protein (p97) is Associated With Lymph Node Metastasis and Prognosis of Pancreatic Ductal Adenocarcinoma. Ann Surg Oncol 11, 165–172 (2004). https://doi.org/10.1245/ASO.2004.05.012
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1245/ASO.2004.05.012